Mabion S.A. Logo

Mabion S.A.

Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.

MAB | WAR

Overview

Corporate Details

ISIN(s):
PLMBION00016 (+1 more)
LEI:
259400KG5JVQPPZL6X53
Country:
Poland
Address:
Konstantynów Łódzki GEN. MARIANA LANGIEWICZA 60, 95-050 Konstantynów Łódzki
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mabion S.A. is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services to pharmaceutical and biotech companies globally. The company specializes in the development, analytics, and manufacturing of complex biologic drugs. Mabion leverages advanced statistical methodologies, such as Design of Experiments (DoE), to optimize bioprocesses, enhance product quality, and ensure regulatory compliance. This data-driven approach supports accelerated development timelines and efficient, robust manufacturing for its partners, demonstrated through its involvement in large-scale production projects for biologics and vaccine components.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-17 14:10
Regulatory News Service
Załącznik 2_Strategia ESG Mabion S.A.
Polish 11.7 MB
2025-11-17 14:10
Regulatory News Service
Załącznik 1_Strategia Mabion S.A.
Polish 1.4 MB
2025-11-17 14:10
Management Discussion and Analysis
Przyjęcie Strategii Spółki Mabion S.A. na lata 2025 - 2030 oraz ujawnienie opóź…
English 8.3 KB
2025-11-17 14:10
Management Discussion and Analysis
Przyjęcie Strategii Spółki Mabion S.A. na lata 2025 - 2030 oraz ujawnienie opóź…
Polish 8.8 KB
2025-10-24 20:35
Related Party Transaction
Zawarcie z Twiti Investments Ltd. umowy pożyczki - Content (EN)
English 2.5 KB
2025-10-24 20:35
Capital/Financing Update
Zawarcie z Twiti Investments Ltd. umowy pożyczki - Content (PL)
Polish 2.4 KB
2025-10-08 15:16
Audit Report / Information
Informacja dotycząca stanowiska Zarządu i opinii Rady Nadzorczej Mabion S.A. od…
Polish 264.8 KB
2025-10-08 15:16
Interim Report
Raport Biegłego Rewidenta
Polish 497.9 KB
2025-10-08 15:16
Interim Report
Oświadczenie Zarządu w sprawie rzetelności sporządzenia sprawozdania finansowego
Polish 228.5 KB
2025-10-08 15:16
Management Discussion and Analysis
Mabion_Sprawozdanie Zarządu_1H2025
Polish 3.2 MB
2025-10-08 15:16
Interim Report
Mabion MSSF_1H2025
Polish 3.4 MB
2025-10-08 15:16
Audit Report / Information
Stanowisko Zarządu i opinia Rady Nadzorczej Mabion S.A. odnoszące się do odmowy…
Polish 368.1 KB
2025-10-08 14:27
Audit Report / Information
Stanowisko Zarządu i opinia Rady Nadzorczej Mabion S.A. odnoszące się do odmowy…
Polish 368.1 KB
2025-10-08 14:27
Audit Report / Information
Uzupełnienie raportu okresowego Spółki za I półrocze 2025 roku - Content (EN)
English 1.0 KB
2025-10-08 14:27
Report Publication Announcement
Uzupełnienie raportu okresowego Spółki za I półrocze 2025 roku - Content (PL)
Polish 784 bytes

Automate Your Workflow. Get a real-time feed of all Mabion S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mabion S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mabion S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea
217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden
KARO
Karyopharm Therapeutics Inc. Logo
Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.
United States of America
KPTI
KAZIA THERAPEUTICS LTD Logo
Oncology-focused drug development firm advancing anti-cancer candidates for brain cancers in trials.
United States of America
KZIA
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea
038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea
256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan
4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland
KNRS
Kiniksa Pharmaceuticals International, plc Logo
Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.
United States of America
KNSA
KIORA PHARMACEUTICALS INC Logo
Developing advanced small molecule therapies for vision-threatening retinal diseases.
United States of America
KPRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.